Inve India ▾

Hester Bios share price & results

Hester Bios· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Gujarat-based maker of animal vaccines, feed supplements and therapeutics for poultry, livestock and pets.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue73.0 ₹ crore+15.9% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin34.0 %+14.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit15.0 ₹ crore+87.5% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity15.42 %+6.5 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin13.98 %−0.4 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)3.83 %+5.1 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

8 of 13 judged targets kept · 2 open · verdicts reflect calls analysed to Q1 FY27.

Hester Bios management guidance track record on Inve: 15 targets tracked across analysed earnings calls (8 achieved, 5 missed, 2 open).

TargetOriginal wordingSaidLatest callVerdict
BSL-3 Facility Revenue Potential ClarityProvide clarity on revenue potential within Q1 or Q2 FY26
Call transcript, Q4 FY25 · 9 May 2025		Q4 FY25Q1 FY27:When asked about BSL3 utilization, management was evasive: 'difficult to give a directional guidance or give you a number... At this point, really cannot give you a capacity utilization percentage'. The lack of clarity persists.
Call transcript, Q1 FY27 · 30 Jul 2026		Missed
Poultry to Animal Healthcare Revenue MixAchieve a 50-50 revenue mix between Poultry and Animal Healthcare
Call transcript, Q4 FY26 · 15 May 2026		Q4 FY26Q1 FY27:The Poultry division grew 48% while the Animal Health division was 'impacted' by tender delays. This has skewed the revenue mix further towards Poultry, moving away from the 50-50 target.
Call transcript, Q1 FY27 · 30 Jul 2026		At Risk
Fill Finish Facility CapitalizationCapitalization by Q2 FY26
Call transcript, Q4 FY25 · 9 May 2025		Q4 FY25Q4 FY26:Management confirms the Fill-Finish facility was capitalized during the year, confirming the delayed completion.
Call transcript, Q4 FY26 · 15 May 2026		Achieved (late)

Source: Inve Guidance Tracker for Hester Bios · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

5 of Hester Bios's 15 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 12 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹2,152.9 +5.48% · +₹111.9

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance +27.8% 1Y

₹1.5k₹2.0k₹2.5kOct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q3 FY26 — 30 Jan 2026Q3 FY26 — 2 Feb 2026Q4 FY26 — 15 May 2026Q1 FY27 — 30 Jul 2026

1Y: ₹1,685 on 24 Oct 2025 → ₹2,152.9. High ₹2,545 (13 Jul 2026), low ₹1,259.1 (30 Mar 2026).

Previous close
₹2,041
Market cap
₹1.8k Cr
52-week range
₹1,259.1 – ₹2,545
One year
+30.74%
Price to earnings (TTM to Jun 2026)
33.60×
Return on equity (TTM to Jun 2026)
15.42%

Overview

Symbol
NSE:HESTERBIO
Exchange
NSE
Currency
INR

What Hester Bios does

Based on the company's own presentations, annual report and earnings calls.

Hester Biosciences develops, manufactures and markets animal-health products — live and inactivated vaccines, feed supplements, therapeutics and biosecurity solutions — for poultry, ruminants and companion animals. It operates through two divisions, Poultry Healthcare and Animal Healthcare (which now includes the Petcare business), and runs three manufacturing plants located in India, Nepal and Africa. The company distributes domestically via its own depot and distributor network and exports to over 35 countries, and is positioned as a leading global supplier of vaccines against diseases such as PPR, Lumpy Skin Disease and Goat Pox.

Segments

  • Poultry Healthcare
  • Animal Healthcare (incl. Petcare)
Manufacturing plants
3 (India, Nepal, Africa)
Installed vaccine production capacity across plants
~11.3 billion doses/year (Mehsana 8.6bn + Nepal 1.24bn + Tanzania 1.5bn)
Countries served (global footprint)
35+
Market position
World's largest supplier of PPR vaccine; largest supplier of LSD vaccine to African countries and Central Asia; largest supplier of Goat Pox vaccine in India; second-largest poultry vaccine manufacturer in India (~35% market share)
India distribution network
15 sales depots, 1,000+ distributors, 250+ field force personnel
Operating legacy
39 years in animal health (serving since 1997)
Headquarters Mehsana, Gujarat, India Company website

How the price took the results

close before → close after

Q1 FY27
−0.7%
30 Jul
Q4 FY26
+5.2%
15 May
Q3 FY26
+3.0%
30 Jan

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Hester Bios

Free account: one company. Everything above stays public.

Write why you follow Hester Bios and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Hester Bios

Guides on how to read this kind of business and the numbers that matter.